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BACKGROUND: Postnatal exposure to perﬂuorinated alkylate substances (PFASs) is associated with lower serum concentrations of speciﬁc antibodies
against certain childhood vaccines at 7 y.
OBJECTIVES:We prospectively followed a Faroese birth cohort to determine these associations at 13 y.
METHODS: In 516 subjects (79% of eligible cohort members) who were 13 years old, serum concentrations of PFASs and of antibodies against diph-
theria and tetanus were measured and were compared with data from the previous examination at 7 y. Multiple regression analyses and structural
equation models were applied to determine the association between postnatal PFAS exposures and antibody concentrations.
RESULTS: Serum concentrations of PFASs and antibodies generally declined from 7 y to 13 y. However, 68 subjects had visited the emergency room
and had likely received a vaccination booster, and a total of 202 children showed higher vaccine antibody concentrations at 13 y than at 7 y.
Therefore, separate analyses were conducted after exclusion of these two subgroups. Diphtheria antibody concentrations decreased at elevated PFAS
concentrations at 13 y and 7 y; the associations were statistically signiﬁcant for perﬂuorodecanoate (PFDA) at 7 y and for perﬂuorooctanoate (PFOA)
at 13 y, both suggesting a decrease by ∼ 25% for each doubling of exposure. Structural equation models showed that a doubling in PFAS exposure at
7 y was associated with losses in diphtheria antibody concentrations at 13 y of 10–30% for the ﬁve PFASs. Few associations were observed for anti-
tetanus concentrations.
CONCLUSIONS: These results are in accord with previous ﬁndings of PFAS immunotoxicity at current exposure levels. https://doi.org/10.1289/
EHP275
Introduction
Perﬂuorinated alkylate substances (PFASs) have a wide range of
applications in water-, soil-, and stain-resistant coatings for cloth-
ing and other textiles and in oil-resistant coatings for food wrap-
ping materials, and their use for >60 y has resulted in worldwide
exposure to these persistent compounds (Lindstrom et al. 2011).
Epidemiological research on possible adverse eﬀects in exposed
populations has intensiﬁed only in recent years (Grandjean and
Clapp 2015; Steenland et al. 2014).
As a measure of depressed immune function, antibody
response to routine childhood vaccinations has been identiﬁed as
a sensitive indicator of elevated PFAS exposures in children
(Grandjean et al. 2012; Granum et al. 2013). Whereas pre-
booster antibody concentrations at 5 y of age appeared to be
aﬀected by both current and prenatal exposures (Grandjean et al.
2012), concentrations at 7 y of age showed inverse associations
mainly with postnatal exposures (Grandjean et al. 2012;
Mogensen et al. 2015). Decreased antibody responses to vaccina-
tions have also been reported in PFAS-exposed adults (Kielsen
et al. 2015; Looker et al. 2014). In addition, elevated PFAS expo-
sures seem to increase the risk of common infections in children
(Granum et al. 2013). Prenatal exposures did not appear to aﬀect
childhood hospitalization rates (Fei et al. 2010), but the quality of
the exposure assessment in the study has recently been called
into doubt (Bach et al. 2015). Because serum PFAS concentra-
tions are often highly correlated, epidemiological studies have
not identiﬁed which PFASs are mainly responsible for the phe-
nomenon, and some studies have therefore modeled total PFAS
exposure (Grandjean et al. 2012; Mogensen et al. 2015). Results
from in vitro studies of human leukocytes support the immuno-
toxic potential of several PFASs, including perﬂuorooctane sulfo-
nate (PFOS), perﬂuorooctanoate (PFOA), and perﬂuorodecanoate
(PFDA) (Corsini et al. 2012), and animal models suggest that
immune depression may occur at serum concentrations of PFOA
and PFOS similar to or slightly above those reported in exposed
human populations (DeWitt et al. 2012).
Immune functions are aﬀected by many diﬀerent kinds of
stimuli (MacGillivray and Kollmann 2014), and speciﬁc antibody
concentrations vary between children with similar vaccination
records; the main determinant of increased concentrations is
recent booster vaccinations (Capua et al. 2013). Although devel-
opmental exposure to polychlorinated biphenyls (PCBs) can also
reduce vaccine responses (Heilmann et al. 2010), PCB concentra-
tions were only weakly associated with PFASs, and adjustment
for prenatal and early postnatal PCB exposure did not materially
aﬀect the PFAS associations with antibody concentrations
(Grandjean et al. 2012).
We have extended our follow-up of the Faroese birth cohort
to the age of 13 y, where we most recently observed strong nega-
tive associations between postnatal serum PFAS concentrations
and antibody concentrations at the age of 7 y (Grandjean et al.
2012; Mogensen et al. 2015). We maintained our focus on tetanus
and diphtheria because these vaccines are toxoids that trigger
complex immune system responses involving both T cells and B
cells (Schatz et al. 1998). Our previous research showed that pre-
natal exposures were particularly linked to the pre-booster anti-
body concentration at 5 y of age, and the concomitant exposure
was associated with the response to the 5-y booster, whereas anti-
body concentrations at 7 y depended mainly on the current expo-
sure levels (Grandjean et al. 2012; Mogensen et al. 2015). We
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therefore focused on the PFAS exposures reﬂected in serum con-
centrations from the two most recent examinations.
Methods
Study Population
A birth cohort of 656 children was compiled from births at the
National Hospital in Tórshavn in the Faroe Islands during 1997–
2000 to explore childhood immune function and the impact on
vaccination eﬃcacy (Grandjean et al. 2012). Faroese children
receive vaccinations against diphtheria and tetanus at 3 mo,
5 mo, and 12 mo, with a booster at 5 y, as part of the
government-supported health care system. All children received
the same amount of vaccine and associated alum adjuvant from
the same source, although additional vaccines (pertussis and
polio) were added to the booster during the project period
(Grandjean et al. 2012). The study protocol was approved by the
Faroese ethics review committee and by the institutional review
board at Harvard T.H. Chan School of Public Health; written
informed consent was obtained from all mothers.
All cohort members were invited for a follow-up examination
at 13 y that included a physical examination and blood sampling.
Information from the children’s mandatory vaccination cards was
copied, and a questionnaire on past medical history and current
health status also included questions about vaccinations adminis-
tered since the previous examination and whether the child had
visited the emergency room. Because tetanus vaccination (which
includes the diphtheria toxoid) in the emergency room is a rou-
tine procedure that may not have been recorded, hospital records
did not contain further information on vaccinations that could be
used for the purposes of the present study.
The PFAS concentrations were measured in serum that was
obtained at the clinical examinations and then frozen at –80C
shortly after separation. We performed online solid-phase extrac-
tion and analysis using high-pressure liquid chromatography with
tandem mass spectrometry (Grandjean et al. 2012). Within-batch
and between-batch imprecision levels (assessed by the coeﬃcient
of variation) were ∼ 5% or better for all analytes. Results with
excellent accuracy have been obtained in regular comparisons
organized by the German Society of Occupational Medicine. The
PFASs quantiﬁed were perﬂuorohexanesulfonic acid (PFHxS),
PFOA, PFOS, perﬂuorononanoate (PFNA), and PFDA.
Serum concentrations of major polychlorinated biphenyl con-
geners were available from maternal pregnancy serum; the sum
of the three major congeners was used as an indicator of the total
PCB exposure as on previous occasions (Grandjean et al. 2012).
Serum concentrations of immunoglobulin G (IgG) antibodies
were measured by the vaccine producer (Statens Serum Institut,
Copenhagen, Denmark) using an enzyme-linked immunosorbent
assay for tetanus and, for diphtheria, a Vero cell–based neutrali-
zation assay using 2-fold dilutions of the serum. For both assays,
calibration was performed using both international and local
standard antitoxins. The methods were the same as those used for
previous examinations (Grandjean et al. 2012).
Statistical Methods
Owing to skewed distributions, the antibody concentrations and
the serum PFAS concentrations measured at 7 y and 13 y were
all log2-transformed before the models were applied. Initial anal-
yses were based on separate multiple linear regressions with age-
13 antibody concentration as the dependent variable and serum
PFAS concentration as a predictor along with age and sex as
mandatory covariates while also considering age-5 booster type
[i.e., co-immunization with other vaccines (Grandjean et al.
2012)]. We included adjustment for prenatal PCB exposure in
separate analyses. We also performed covariate-adjusted logistic
regression analyses to determine the odds ratios for each age-13
vaccine antibody concentration being below the clinically protec-
tive level of 0.1 IU/mL with a doubled PFAS exposure. Using
structural equation models (Mogensen et al. 2015), we deter-
mined the associations of the age-7 PFAS concentrations with the
speciﬁc antibody levels at 13 y. We modeled these associations
as an indirect eﬀect (via the antibody result at 7 y) and as a total
eﬀect. The total eﬀect has the same interpretation as a linear
regression model without the adjustment for the antibody level at
7 y, but it provides a more stable measure with better error con-
trol. The indirect eﬀect is the loss in antibody concentration at
13 y due to increases in PFAS at 7 y being associated with lower
antibody concentrations at that age, with these antibody concen-
trations being associated with the levels at 13 y. In addition, in a
separate model, we ignored the direct path from PFAS exposure
at 7 y to the antibody concentration at 13 y. All models were
adjusted for sex and age as covariates, and incomplete observa-
tions were included assuming that information was missing at
random, thus allowing calculations based on the maximum likeli-
hood principle (Rubin 1987).
For comparison, we also applied linear mixed models to as-
certain the eﬀects of age-7 serum PFAS concentrations on the
antibody outcomes at 7 and 13 y. Interaction between exposure
and age was included, and the results were again adjusted for
both age and sex. The assumption of linear dose–response associ-
ations was veriﬁed by allowing for a more ﬂexible relationship
between the PFAS and antibody concentrations in generalized
additive models using cubic regression splines with three knots
(Hastie and Tibshirani 1990); no signiﬁcant deviation from line-
arity was found. Because both PFAS concentrations and antibody
outcomes were log2-transformed, we expressed the regression
coeﬃcients as the change in the antibody concentration in percent
for each doubling of the exposure.
Results
A total of 516 children (78.7% of the cohort members) partici-
pated in the age-13 examinations, and 587 (89.0%) participated
either at 7 y or at 13 y or both. The characteristics of the children
who provided suﬃcient serum for analyses at 13 y are shown in
Table 1. PFOS was by far the most prevalent PFAS, with a me-
dian serum concentration at 13 y of 6:7 ng=mL, a 56% decrease
since 7 y. PFOA and PFNA decreased to a similar extent.
Although the correlation between the age-7 and age-13 concen-
trations of the same PFAS was even closer than the correlation
between the diﬀerent PFASs at each age (r  0:85 at 13 y and
0:62 at 7 y), the close correlations prevented meaningful adjust-
ment for concomitant PFAS exposures. In contrast, the PCB con-
centration in maternal pregnancy serum correlated poorly with
the child’s serum PFAS concentrations at 7 y (r between − 0:06
and 0.15) and 13 y (r between 0.11 and 0.20).
On average, both antibody concentrations showed clear
decreases during the six-year period from 7 y to 13 y, although they
were stronger for diphtheria (Table 1).At 13y, 207 (39.4%) and103
(19.6%) children had antibody concentrations <0:1 IU=mL for
diphtheria and for tetanus, respectively. However, not all children
showed the anticipated decrease in antibody concentrations. Scatter
plots of the correlation between antibody concentrations at 7 y and
13 y show that concentrations increased between the two examina-
tions in many cohort subjects (Figure 1). An increase in antibody
concentration could likely be a result of additional antigen expo-
sure, most likely because some subjects had received an unsched-
uled booster dose. Six of the children had received an additional
booster at the project clinic because of their very low antibody
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concentrations after the age-5 booster. Questionnaire information
further revealed that 68 cohort members had visited the emergency
roomwhere they likely received a tetanus booster shot, and indeed,
many of them had elevated antibody concentrations at age 13
(Figure 1). Nevertheless, a total of 202 children did not show the
anticipated decrease in antibody concentrations between 7 y and
13 y,most ofwhomwere not known to have been vaccinated after 5
y. Statistical analyses were therefore performed on the whole
Table 1. Characteristics of children who contributed serum-antibody concentrations at the two follow-up examinations.
Variable
Total cohort (n=587) No ER visit (n=519)
No ER visits and no antibody
increase (n=317)
n Summary n Summary n Summary
Sex, n (%) (Girls) 587 (100%) 278 (47.4%) 519 (100%) 238 (45.9%) 317 (100%) 147 (46.4%)
Booster type 1, n (%) (yes) 575 (98.0%) 412 (71.7%) 509 (98.1%) 367 (72.1%) 311 (98.1%) 209 (67.2%)
Age, median (IQR) (years)
Current examination 516 (87.9%) 13.2 (12.9; 13.6) 448 (86.3%) 13.2 (12.9; 13.6) 317 (100%) 13.3 (13.0; 13.6)
Age-7 examination 565 (96.3%) 7.5 (7.5; 7.6) 497 (95.8%) 7.5 (7.5; 7.6) 317 (100%) 7.5 (7.5; 7.6)
Antibody concentrations, median (IQR) (IU/mL)
Anti-diphtheria at 13 y 515 (87.7%) 0.1 (0.0; 0.2) 447 (86.1%) 0.1 (0.0; 0.2) 317 (100%) 0.1 (0.0; 0.2)
Anti-diphtheria at 7 y 459 (78.2%) 0.8 (0.4; 1.6) 391 (75.3%) 0.8 (0.4; 1.6) 317 (100%) 0.8 (0.4; 1.6)
Anti-tetanus at 13 years 515 (87.7%) 0.6 (0.3; 1.8) 447 (86.1%) 0.5 (0.3; 1.2) 317 (100%) 0.5 (0.2; 1.0)
Anti-tetanus at 7 y 459 (78.2%) 1.8 (0.6; 4.5) 391 (75.3%) 2.1 (1.1; 5.2) 317 (100%) 2.3 (1.3; 5.5)
PFAS concentrations, median (IQR) (ng/mL)
PFOS at 13 years 515 (87.7%) 6.7 (5.2; 8.5) 447 (86.1%) 6.7 (5.3; 8.5) 317 (100%) 6.8 (5.4; 8.7)
PFOS at 7 y 488 (83.1%) 15.3 (12.4; 19.0) 420 (80.9%) 15.3 (12.4; 19.0) 312 (98.4%) 15.5 (12.9; 18.9)
PFOA at 13 y 515 (87.7%) 2.0 (1.6; 2.5) 447 (86.1%) 2.0 (1.5; 2.5) 317 (100%) 2.0 (1.6; 2.6)
PFOA at 7 y 488 (83.1%) 4.4 (3.5; 5.7) 420 (80.9%) 4.4 (3.6; 5.7) 312 (98.4%) 4.4 (3.5; 5.5)
PFHxS at 13 y 515 (87.7%) 0.4 (0.3; 0.5) 447 (86.1%) 0.4 (0.3; 0.5) 317 (100%) 0.4 (0.3; 0.5)
PFHxS at 7 y 488 (83.1%) 0.5 (0.4; 0.7) 420 (80.9%) 0.5 (0.4; 0.7) 312 (98.4%) 0.5 (0.4; 0.7)
PFNA at 13 y 515 (87.7%) 0.7 (0.6; 0.9) 447 (86.1%) 0.7 (0.6; 0.9) 317 (100%) 0.8 (0.6; 1.0)
PFNA at 7 y 488 (83.1%) 1.1 (0.9; 1.5) 420 (80.9%) 1.1 (0.9; 1.5) 312 (98.4%) 1.1 (0.9; 1.5)
PFDA at 13 y 515 (87.7%) 0.3 (0.2; 0.4) 447 (86.1%) 0.3 (0.2; 0.4) 317 (100%) 0.3 (0.2; 0.4)
PFDA at 7 y 488 (83.1%) 0.4 (0.2; 0.6) 420 (80.9%) 0.4 (0.2; 0.5) 312 (98.4%) 0.4 (0.2; 0.5)
Note: ER, emergency room; IQR, interquartile range; IU, international units; PFAS, perflourinated alkylate substance; PFDA, perfluorodecanoate; PFHxS, perfluorohexanesulfonic
acid; PFNA, perfluorononanoate; PFOA, perflourooctanoate; PFOS, perfluorooctane sulfonate.
Figure 1. Scatter plot showing paired antibody concentrations for diphtheria (left) and tetanus (right) in children examined at both 7 y and 13 y.
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group; after exclusion of subjectswith a record of having visited the
emergency room or otherwise having received an additional
booster (no-ER group); and, for comparison purposes, after exclu-
sion of the 202 subjects who for unknown reason did not show the
anticipated decrease in antibody concentrations between 7 y and
13 y. These three groupswere fairly similar with regard to sex, age,
andPFASexposure (Table 1).
Multiple regression analyses showed a uniformly inverse
association between anti-diphtheria antibody concentrations at 13
y and the PFAS concentrations at either 7 y or 13 y (Table 2).
The tendencies were the strongest after exclusion of subjects with
a history of an additional booster, and an approximately 25%
decrease for each doubling in serum PFOA concentration at 13 y
and a 24% decrease for each doubling in serum PFDA concentra-
tion at 7 y were both statistically signiﬁcant. However, tetanus
antibody concentrations, which had decreased much less than
diphtheria antibody concentrations, tended to show positive asso-
ciations, one of which was statistically signiﬁcant (Table 3). As
expected (Grandjean et al. 2012), adjustment for developmental
PCB exposure had no appreciable eﬀect on these associations;
therefore, PCB was not considered further. Logistic regression
analyses of the results, many of which were close to the 0.1 IU/mL
limit, inmost cases showed odds close to 1 for the antibody concen-
trations being below the clinically protective level (data not
shown). However, for diphtheria, a doubled concomitant serum
PFOA concentration showed odds ratios of 1.47 (95% CI: 1.03,
2.14; p=0:038) and 1.71 (95% CI: 1.15, 2.55; p=0:008) for a
nonprotective antibody level in the total study group and in the no-
ER group, respectively. Further, PFDA at 7 y showed statistically
signiﬁcant odds ratios of 1.39 (95% CI: 1.05, 1.85; p=0:023) and
1.54 (95%CI: 1.13, 2.12; p=0:007) for diphtheria in the same two
groups, respectively; no other associations reached statistical
signiﬁcance.
In the ﬁrst structural equation model, we included an indirect
eﬀect mediated by the exposure at 7 y via the antibody concentra-
tion at that age. Tables 4 and 5 show the indirect eﬀect and the total
eﬀect observed in this model. For diphtheria, all associations were
inverse, and all ﬁve PFASs showed statistically signiﬁcant inverse
associations in the no-ER group. Tendencies were weaker in the
total group and after exclusion of subjects without decreasing anti-
body concentrations. For tetanus, some inverse associations were
observed, although nonewas signiﬁcant. A secondmodelwithout a
direct eﬀect ﬁtted the data equally well and showed a similar,
though stronger, indirect eﬀect for diphtheria via the age-7 antibody
concentration. These tendencies also became clear for tetanus,
where statistically signiﬁcant indirect eﬀects were now apparent in
the no-ER group, both for PFOA (–24:2; 95% CI: − 41:1, − 2:4)
and for PFHxS (–25:1; 95% CI: − 38:9, − 8:3). Finally, the results
obtained with the linear mixed models were similar to those
obtainedwith theﬁrst structural equationmodel.
Table 2. Linear regression models of changes in anti-diphtheria concentrations at 13 y associated with serum PFAS concentrations 13 y and 7 y adjusted for
sex, age at antibody assessment, and booster type.
PFAS (ng/mL)
Total cohort (n=587) No booster or ER visit (n=519)
No booster or ER visit and no antibody
increase (n=317)
n Change 95% CI p-value n Change 95% CI p-value n Change 95% CI p-value
PFAS concentrations, 13 y
PFOS 505 −8.6 −27.7, 15.6 0.454 439 −10.5 −29.8, 14.3 0.374 311 −0.6 −24.5, 30.9 0.965
PFOA 505 −17.5 −35.6, 5.8 0.129 439 −25.3 −42.5, −3.0 0.029 311 −17.8 −38.0, 9.0 0.173
PFHxS 505 −5.5 −22.9, 15.8 0.583 439 −10.9 −27.7, 9.8 0.279 311 −0.2 −20.4, 25.0 0.984
PFNA 505 −4.5 −24.2, 20.2 0.693 439 −6.6 −26.7, 19.0 0.579 311 −3.7 −25.8, 25.2 0.780
PFDA 505 −3.7 −22.0, 18.9 0.726 439 −3.5 −22.5, 20.3 0.754 311 −4.4 −24.9, 21.8 0.716
PFAS concentrations, 7 y
PFOS 427 −23.8 −43.2, 2.3 0.070 361 −25.6 −45.4, 1.4 0.061 306 −10.8 −35.6, 23.5 0.490
PFOA 427 −4.1 −25.4, 23.3 0.742 361 −9.2 −30.7, 18.8 0.480 306 −2.7 −26.4, 28.5 0.845
PFHxS 427 −10.2 −25.7, 8.5 0.264 361 −16.3 −31.3, 2.0 0.077 306 −5.9 −23.4, 15.4 0.556
PFNA 427 −11.3 −27.4, 8.5 0.243 361 −13.6 −30.6, 7.5 0.190 306 −7.0 −25.6, 16.1 0.519
PFDA 427 −21.5 −34.4, −6.0 0.008 361 −24.2 −37.5, −8.0 0.005 306 −19.7 −34.0, −2.2 0.029
Note: The change in the antibody concentration is expressed in percent per doubling of the serum PFAS concentration at the two different ages. CI, confidence interval; ER, emergency
room; PFAS, perflourinated alkylate substance; PFDA, perfluorodecanoate; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoate; PFOA, perflourooctanoate; PFOS, per-
fluorooctane sulfonate.
Table 3. Linear regression models of changes in anti-tetanus concentrations at 13 y associated with serum-PFAS concentrations at 13 y and 7 y adjusted for
sex, age at antibody assessment, and booster type.
PFAS (ng/mL)
Total cohort (n=587) No ER visit (n=519)
No ER visit and no antibody increase
(n=317)
n Change 95% CI p-value n Change 95% CI p-value n Change 95% CI p-value
PFAS concentrations, 13 y
PFOS 505 22.2 −12.4, 70.3 0.237 439 23.4 −7.0, 63.7 0.144 311 14.8 −8.7, 44.4 0.236
PFOA 505 3.3 −27.3, 46.9 0.856 439 −5.6 −30.5, 28.1 0.710 311 −16.1 −33.7, 6.3 0.145
PFHxS 505 8.7 −18.5, 45.0 0.568 439 19.3 −6.4, 52.1 0.153 311 1.8 −15.6, 22.9 0.851
PFNA 505 15.2 −16.9, 59.7 0.394 439 5.1 −20.7, 39.3 0.727 311 11.6 −10.3, 38.8 0.324
PFDA 505 18.7 −11.8, 59.8 0.258 439 6.9 −17.2, 38.0 0.607 311 18.0 −3.5, 44.4 0.106
PFAS concentrations, 7 y
PFOS 427 30.0 −16.1, 101.4 0.240 361 45.4 1.2, 108.8 0.043 306 2.7 −21.8, 34.8 0.849
PFOA 427 9.4 −24.7, 58.9 0.637 361 2.9 −25.0, 41.1 0.859 306 −4.9 −24.6, 20.0 0.671
PFHxS 427 14.8 −13.3, 52.2 0.334 361 25.2 −0.6, 57.7 0.057 306 −11.3 −25.2, 5.2 0.167
PFNA 427 31.0 −2.7, 76.4 0.075 361 23.1 −4.6, 59.0 0.110 306 11.9 −7.1, 34.7 0.235
PFDA 427 36.8 4.7, 78.7 0.022 361 25.1 −0.4, 57.0 0.054 306 3.5 −12.3, 22.2 0.682
Note: The change in the antibody concentration is expressed in percent per doubling of the serum PFAS concentration at the two different ages. CI, confidence interval; ER, emergency
room; PFAS, perflourinated alkylate substance; PFDA, perfluorodecanoate; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoate; PFOA, perflourooctanoate; PFOS, per-
fluorooctane sulfonate.
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Discussion
The present prospective study was performed in adolescents to
ascertain PFAS-associated decreases in antibody responses to
their childhood vaccines. Owing to numerous unscheduled
booster vaccinations, the data were censored to remove co-
hort members with records of emergency room visits. In this
subgroup, multiple regression results showed that diphtheria anti-
body concentrations decreased at elevated serum PFAS concen-
trations at 13 y and 7 y; the associations were statistically
signiﬁcant for PFDA at 7 y and for PFOA at 13 y, both suggest-
ing a decrease by ∼ 25% for each doubling of exposure. The
ﬁndings after exclusion of all subjects without a decrease in anti-
body concentrations were less clear. Structural equation models
showed that a doubling of PFAS exposure at 7 y was associated
with statistically signiﬁcant losses in diphtheria antibody concen-
trations at 13 y of 10–30% for the ﬁve PFASs. Few associations
were observed for anti-tetanus concentrations. However, more
advanced modeling showed negative associations for tetanus
with regard to the age-7 PFAS exposure. Owing to the intercorre-
lations between the serum PFAS concentrations, further analysis
of the possible role of individual PFASs was not pursued, and the
observed associations may reﬂect the eﬀects of the PFAS
mixtures.
Although the present study aimed to obtain prospective data
on the associations between PFAS exposure and vaccine antibody
concentration over an extended period, an antibody concentration
at a particular point in time does not represent the complete tra-
jectory of changes and may not be representative of the protec-
tion against the speciﬁc disease in the long term. The present
prospective study is apparently the ﬁrst to elucidate the temporal
changes in antibody concentrations in relation to PFAS immuno-
toxicity through to adolescence. A major obstacle in such obser-
vational studies is that children and adolescents who visit the
emergency room for cuts and other injuries are routinely adminis-
tered a tetanus booster, which also aﬀects diphtheria because
both toxoids are present in the vaccine, thereby interfering with
the study design. We therefore chose to exclude subjects who had
a record of an emergency room visit (to obtain no-ER group). For
comparison, we performed parallel calculations after excluding
>200 subjects who had not revealed the anticipated decrease in
antibody concentrations between 7 y and 13 y. With antibody
concentrations that decrease to diﬀerent degrees over time and
with PFAS exposure levels that likewise show decreases, multi-
ple regression analyses of the bivariate data sets need to be com-
plemented by more-advanced modeling.
Our study is limited to PFAS exposure assessments at two
points during childhood at an interval of approximately six years.
Although the elimination half-lives of the PFASs are 2–5 y
(Bartell et al. 2010; Olsen et al. 2007), the two widely separated
measurements may not fully characterize the childhood exposure
proﬁle. Because exposures during childhood are likely to vary
(Kato et al. 2009; Lindstrom et al. 2011), it is possible that serial
serum PFAS analyses would provide stronger evidence for PFAS
immunotoxicity. However, given that a decreased antibody con-
centration is most likely due to past exposures, rather than to cur-
rent, lower exposures (Mogensen et al. 2015), we chose to rely
on the age-7 exposure levels and to include both antibody
Table 5. Effects of serum-PFAS concentrations at 7 y on anti-tetanus antibody concentrations at 7 y and 13 y adjusted for age and sex in structural equation
models.
PFAS (ng/mL) Effect
Total cohort (n=587) No ER visit (n=519)
No ER visit and no antibody increase
(n=317)
Change 95% CI p-value Change 95% CI p-value Change 95% CI p-value
PFOS Indirect 3.2 −5.7, 12.9 0.492 −2.2 −6.5, 2.4 0.347 −1.4 −21.7, 24.2 0.906
Total 26.3 −17.2, 92.6 0.278 42.9 −2.8, 110.0 0.069 2.1 −21.5, 32.9 0.877
PFOA Indirect 6.0 −1.9, 14.4 0.138 −3.2 −7.7, 1.5 0.181 −16.0 −30.7, 1.8 0.075
Total 11.3 −22.3, 59.3 0.560 1.9 −27.3, 42.6 0.915 −7.2 −25.5, 15.6 0.505
PFHxS Indirect 7.7 0.6, 15.3 0.033 −3.7 −8.1, 0.8 0.107 −12.4 −24.2, 1.2 0.072
Total 14.1 −13.1, 49.8 0.342 25.0 −2.3, 59.8 0.075 −12.1 −25.4, 3.7 0.127
PFNA Indirect 1.0 −4.7, 6.9 0.739 −1.1 −3.8, 1.6 0.416 4.2 −10.9, 21.9 0.604
Total 28.9 −3.1, 71.5 0.081 23.6 −6.0, 62.5 0.129 12.7 −5.8, 34.8 0.190
PFDA Indirect −0.8 −5.4, 4.0 0.729 0.1 −1.8, 2.0 0.936 7.8 −4.7, 21.8 0.231
Total 27.5 −0.3, 62.9 0.053 16.7 −7.7, 47.5 0.196 2.7 −11.1, 18.5 0.721
Note: The change in the anti-tetanus concentration is expressed in percent per doubling of the age-7 serum PFAS concentration. CI, confidence interval; ER, emergency room; PFAS,
perflourinated alkylate substance; PFDA, perfluorodecanoate; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoate; PFOA, perflourooctanoate; PFOS, perfluorooctane
sulfonate.
Table 4. Effects of serum-PFAS concentrations at 7 y on anti-diphtheria antibody concentrations at 7 y and 13 y adjusted for age and sex in structural equation
models.
PFAS (ng/mL) Effect
Total cohort (n=587) No ER visit (n=519)
No ER visit and no antibody increase
(n=317)
Change 95% CI p-value Change 95% CI p-value Change 95% CI p-value
PFOS Indirect −29.7 −44.3, −11.3 0.003 −32.8 −47.9, −13.3 0.002 −22.3 −40.3, 1.2 0.061
Total −26.5 −45.7, −0.5 0.046 −31.1 −49.8, −5.4 0.021 −16.0 −38.8, 15.4 0.282
PFOA Indirect −17.7 −32.24, −0.0 0.050 −19.8 −35.4, −0.5 0.045 −15.0 −31.8, 5.9 0.147
Total −4.3 −26.0, 23.8 0.739 −9.4 −31.1, 19.2 0.481 −5.8 −27.8, 22.9 0.661
PFHxS Indirect −13.4 −25.9, 1.2 0.071 −16.2 −29.3, −0.6 0.042 −8.6 −22.6, 7.9 0.289
Total −12.0 −28.0, 7.5 0.211 −19.5 −34.7, −0.7 0.043 −8.0 −24.6, 12.4 0.415
PFNA Indirect −20.7 −31.8, −7.8 0.003 −23.3 −35.3, −9.0 0.002 −18.1 −31.6, −1.9 0.030
Total −15.6 −31.1, 3.2 0.099 −17.4 −33.7, 2.8 0.087 −9.4 −27.0, 12.5 0.371
PFDA Indirect −19.6 −28.8, −9.2 <0.001 −20.7 −30.7, −9.2 0.001 −17.0 −27.8, −4.7 0.008
Total −22.5 −34.5, −8.3 0.003 −25.1 −37.3, −10.4 0.002 −19.8 −32.6, −4.6 0.013
Note: The change in the anti-diphtheria concentration is expressed in percent per doubling of the age-7 serum PFAS concentration. CI, confidence interval; ER, emergency room;
PFAS, perflourinated alkylate substance; PFDA, perfluorodecanoate; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoate; PFOA, perflourooctanoate; PFOS, perfluor-
ooctane sulfonate.
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measurements at 7 y and 13 y in the assessment. At age 7, con-
current serum PFAS concentrations showed strong inverse asso-
ciations with vaccine antibody concentrations, and inclusion of
age-5 PFAS concentrations slightly strengthened these tendencies
(Mogensen et al. 2015).
The 5-y booster vaccination is in principle the last booster
vaccination that a child receives, and long-term protection is
therefore intended. Our previous results (Grandjean et al. 2012)
showed that at 7 y, many children had antibody concentrations
below the level assumed to provide the desired protection. The
number of children with antibody concentrations below the
desired level had substantially increased by age 13 and was simi-
lar to the number of children with antibody concentrations below
the level of protection at age 5 before the booster. These observa-
tions support the justiﬁcation for routinely supplying a booster
vaccination in the emergency room in connection with any in-
jury that may have involved the slightest risk of tetanus.
Unfortunately, such preventive measures add variance to the
present study design, which relied on all children being vacci-
nated at the same age and with the same antigen dose. The study
assumption was therefore violated, and it proved to be diﬃcult to
adjust for additional immunizations at diﬀerent ages given the
incomplete knowledge of booster administrations. Accordingly,
the results clearly show the strongest associations between PFAS
exposure and antibody concentrations in cohort subjects who
were not known to have visited the emergency room or to other-
wise have received a booster. However, Figure 1 also shows an
increased antibody concentration at 13 y in many cohort mem-
bers, possibly resulting from a booster that had not been
recorded. Exclusion of all cohort members without an apparent
decrease in antibody concentration at 13 y may have more than
remedied this problem because it most likely excluded too many
subjects, thereby attenuating the statistical power. As might be
expected, the results for the most restricted subgroup are
somewhat weaker than those for the less restricted cohort.
Nevertheless, the increased antibody concentration in children
who had received a booster suggests that any adverse inﬂuences
of PFAS exposure could be remedied by repeated antigen chal-
lenge, although such intervention might not compensate for any
other adverse eﬀects associated with PFAS immunotoxicity.
As in previous studies (Grandjean et al. 2012; Mogensen
et al. 2015), we found stronger associations for diphtheria than
for tetanus. The former also exhibited much greater decreases
from 7 y to 13 y, most likely because the diphtheria toxoid is a
weaker antigen than tetanus and is therefore more easily aﬀected
by PFAS-depressed immune function. The exact magnitude of
the serum antibody concentration may not be clinically impor-
tant, but very low levels will result in poor or absent protection.
With many antibody concentrations being close to the assumed
clinically protective level of 0.1 IU/mL, logistic regression
showed only weak tendencies for antibody levels below the limit
to be associated with serum PFAS concentrations. Similarly,
imprecision of antibody assessments, particularly at concentra-
tions below or close to the clinically protective concentration,
may have biased the regression analyses toward the null.
In support of our ﬁndings of PFAS immunotoxicity, a study
of 99 Norwegian children at 3 y found that the maternal serum
PFOA concentrations were associated with decreased vaccine
responses in the children, particularly toward rubella vaccine, as
well as increased frequencies of common cold and gastroenteritis
(Granum et al. 2013). However, PFOS and PFOA concentrations
in serum from 1,400 pregnant women from the Danish National
Birth Cohort were not associated with the total hospitalization
rate for a variety of infectious diseases in 363 of the children up
to an average age of 8 y (Fei et al. 2010). However, the validity
of this study has been questioned owing to the poor stability of
the serum PFAS measurements (Bach et al. 2015); such impreci-
sion of the exposure assessment could easily bias the results to-
ward the null (Grandjean and Budtz-Jørgensen 2010).
In adults, PFOA exposure from contaminated drinking water
was associated with lower serum concentrations of total IgA and
IgE (in females only), although not of total IgG (Fletcher et al.
2009). More speciﬁcally, a reduced antibody titer increase after
inﬂuenza vaccination was found in the most highly exposed sub-
jects (Looker et al. 2014). Further, a small intervention study of
12 adults showed that the time-dependent increase in vaccine-
speciﬁc antibody concentrations decreased at higher PFAS expo-
sures (Kielsen et al. 2015). Overall, support is building for the
notion that PFAS exposure is associated with deﬁcient immune
function. Although diphtheria and perhaps tetanus may not be
likely hazards in the Faroese and in the residents of many other
countries, the strongly decreased antibody concentrations likely
reﬂect an immunological deﬁcit. Because optimal immune sys-
tem function is crucial for health, the associations identiﬁed
should be regarded as adverse. We recently calculated benchmark
dose levels to estimate the magnitude of exposure limits that
would protect against the immunotoxicity observed. The results
suggested that the present exposure limits may be too high by a
factor of 100 (Grandjean and Budtz-Jørgensen 2013). The present
study extends the previous ﬁndings of deﬁcient antibody
responses in this cohort at younger ages and therefore adds sup-
port to the notion that substantially strengthened prevention of
PFAS exposure is indicated.
Conclusions
The results of the present study are in accordwith previous ﬁndings
of PFAS immunotoxicity at current exposure levels, although the
results of this observational study are aﬀected by concomitant
decreases in concentrations of both PFASs and antibodies and by
known and suspected booster vaccinations during the eight-year
interval since the routine5-ybooster.
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